Metastatic Prostatic Ductal Adenocarcinoma Successfully Treated with Docetaxel Chemotherapy: A Case Report
A 68-year-old man presented with gross hematuria. A papillary urethral tumor adjacent to the verumontanum was found by cystourethroscopy. Serum prostate-specific antigen (PSA) was 3.246 ng/ml. A transurethral biopsy specimen was most suggestive of a primary urothelial carcinoma of the prostate, for...
Gespeichert in:
| Veröffentlicht in: | Case reports in oncology 2015-08, Vol.8 (2), p.339-344 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 344 |
|---|---|
| container_issue | 2 |
| container_start_page | 339 |
| container_title | Case reports in oncology |
| container_volume | 8 |
| creator | Fujiwara, Ryo Kageyama, Susumu Tomita, Keiji Hanada, Eiki Tsuru, Teruhiko Yoshida, Tetsuya Narita, Mitsuhiro Isono, Takahiro Kawauchi, Akihiro |
| description | A 68-year-old man presented with gross hematuria. A papillary urethral tumor adjacent to the verumontanum was found by cystourethroscopy. Serum prostate-specific antigen (PSA) was 3.246 ng/ml. A transurethral biopsy specimen was most suggestive of a primary urothelial carcinoma of the prostate, for which a radical cystoprostatectomy was performed. The final pathology was prostatic ductal adenocarcinoma with very focal acinar features (Gleason score 5 + 4 = 9, pT3bN0M0). Local recurrence and pelvic bone metastases developed 17 months later, and his PSA rose to 10.806 ng/ml. He was treated with combined androgen blockade and radiation. Two years later, the lesion showed progressive growth. Treatment followed with docetaxel (70 mg/m 2 every 3 weeks) and prednisolone 5 mg twice daily. After 10 cycles of chemotherapy, all lesions disappeared and PSA decreased to |
| doi_str_mv | 10.1159/000438785 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1159_000438785</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_e1d9e399dc8a48b79d7990118362496d</doaj_id><sourcerecordid>26351443</sourcerecordid><originalsourceid>FETCH-LOGICAL-c457t-1eafa6bce65973bd5fa540cf912275f1e01f4722255fdd6560a14887e761057a3</originalsourceid><addsrcrecordid>eNptkU1vEzEQhi0EoqVw4I6QJU4cAvauP9YcKkVbPioVFZVytib2ONmwiVdeB8i_x7AhaiVOHtmPnxn7JeQ5Z284l-YtY0zUjW7kA3LKlapmSmr58E59Qp6M45oxZaSSj8lJpWrJhahPyfozZhgz5M7RLykeqoudy9DTucdtdJBct40boF93zuE4hl3f7-ltQsjo6c8ur-hFdEXzC3varnAT8woTDPt3dE5bGJHe4BBTfkoeBehHfHZYz8i3D-9v20-zq-uPl-38auaE1HnGEQKohUMlja4XXgaQgrlgeFVpGTgyHoSuqkrK4L2SigEXTaNRK86khvqMXE5eH2Fth9RtIO1thM7-3YhpaSGVV_ZokXuDtTHeNSCahTZeG8M4b2pVCaN8cZ1PrmG32KB3uM0J-nvS-yfbbmWX8YcVZa6a8SJ4PQlc-dwxYTje5cz-Cc8ewyvsy7vNjuS_tArwagK-Q1piOgLtzfWksIMPhXrxX-rQ5TcH-Kq_</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Metastatic Prostatic Ductal Adenocarcinoma Successfully Treated with Docetaxel Chemotherapy: A Case Report</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Karger Open Access</source><source>PubMed Central</source><creator>Fujiwara, Ryo ; Kageyama, Susumu ; Tomita, Keiji ; Hanada, Eiki ; Tsuru, Teruhiko ; Yoshida, Tetsuya ; Narita, Mitsuhiro ; Isono, Takahiro ; Kawauchi, Akihiro</creator><creatorcontrib>Fujiwara, Ryo ; Kageyama, Susumu ; Tomita, Keiji ; Hanada, Eiki ; Tsuru, Teruhiko ; Yoshida, Tetsuya ; Narita, Mitsuhiro ; Isono, Takahiro ; Kawauchi, Akihiro</creatorcontrib><description>A 68-year-old man presented with gross hematuria. A papillary urethral tumor adjacent to the verumontanum was found by cystourethroscopy. Serum prostate-specific antigen (PSA) was 3.246 ng/ml. A transurethral biopsy specimen was most suggestive of a primary urothelial carcinoma of the prostate, for which a radical cystoprostatectomy was performed. The final pathology was prostatic ductal adenocarcinoma with very focal acinar features (Gleason score 5 + 4 = 9, pT3bN0M0). Local recurrence and pelvic bone metastases developed 17 months later, and his PSA rose to 10.806 ng/ml. He was treated with combined androgen blockade and radiation. Two years later, the lesion showed progressive growth. Treatment followed with docetaxel (70 mg/m 2 every 3 weeks) and prednisolone 5 mg twice daily. After 10 cycles of chemotherapy, all lesions disappeared and PSA decreased to <0.005 ng/ml. Three years after chemotherapy, he maintains a complete response without any additional treatments. Docetaxel chemotherapy can be an effective treatment for patients with recurrent prostatic ductal adenocarcinoma.</description><identifier>ISSN: 1662-6575</identifier><identifier>EISSN: 1662-6575</identifier><identifier>DOI: 10.1159/000438785</identifier><identifier>PMID: 26351443</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Chemotherapy ; Docetaxel ; Prostatic ductal adenocarcinoma ; Published: August 2015</subject><ispartof>Case reports in oncology, 2015-08, Vol.8 (2), p.339-344</ispartof><rights>2015 S. Karger AG, Basel</rights><rights>Copyright © 2015 by S. Karger AG, Basel 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c457t-1eafa6bce65973bd5fa540cf912275f1e01f4722255fdd6560a14887e761057a3</citedby><cites>FETCH-LOGICAL-c457t-1eafa6bce65973bd5fa540cf912275f1e01f4722255fdd6560a14887e761057a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4560301/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4560301/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,861,882,2096,27616,27905,27906,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26351443$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fujiwara, Ryo</creatorcontrib><creatorcontrib>Kageyama, Susumu</creatorcontrib><creatorcontrib>Tomita, Keiji</creatorcontrib><creatorcontrib>Hanada, Eiki</creatorcontrib><creatorcontrib>Tsuru, Teruhiko</creatorcontrib><creatorcontrib>Yoshida, Tetsuya</creatorcontrib><creatorcontrib>Narita, Mitsuhiro</creatorcontrib><creatorcontrib>Isono, Takahiro</creatorcontrib><creatorcontrib>Kawauchi, Akihiro</creatorcontrib><title>Metastatic Prostatic Ductal Adenocarcinoma Successfully Treated with Docetaxel Chemotherapy: A Case Report</title><title>Case reports in oncology</title><addtitle>Case Rep Oncol</addtitle><description>A 68-year-old man presented with gross hematuria. A papillary urethral tumor adjacent to the verumontanum was found by cystourethroscopy. Serum prostate-specific antigen (PSA) was 3.246 ng/ml. A transurethral biopsy specimen was most suggestive of a primary urothelial carcinoma of the prostate, for which a radical cystoprostatectomy was performed. The final pathology was prostatic ductal adenocarcinoma with very focal acinar features (Gleason score 5 + 4 = 9, pT3bN0M0). Local recurrence and pelvic bone metastases developed 17 months later, and his PSA rose to 10.806 ng/ml. He was treated with combined androgen blockade and radiation. Two years later, the lesion showed progressive growth. Treatment followed with docetaxel (70 mg/m 2 every 3 weeks) and prednisolone 5 mg twice daily. After 10 cycles of chemotherapy, all lesions disappeared and PSA decreased to <0.005 ng/ml. Three years after chemotherapy, he maintains a complete response without any additional treatments. Docetaxel chemotherapy can be an effective treatment for patients with recurrent prostatic ductal adenocarcinoma.</description><subject>Chemotherapy</subject><subject>Docetaxel</subject><subject>Prostatic ductal adenocarcinoma</subject><subject>Published: August 2015</subject><issn>1662-6575</issn><issn>1662-6575</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>M--</sourceid><sourceid>DOA</sourceid><recordid>eNptkU1vEzEQhi0EoqVw4I6QJU4cAvauP9YcKkVbPioVFZVytib2ONmwiVdeB8i_x7AhaiVOHtmPnxn7JeQ5Z284l-YtY0zUjW7kA3LKlapmSmr58E59Qp6M45oxZaSSj8lJpWrJhahPyfozZhgz5M7RLykeqoudy9DTucdtdJBct40boF93zuE4hl3f7-ltQsjo6c8ur-hFdEXzC3varnAT8woTDPt3dE5bGJHe4BBTfkoeBehHfHZYz8i3D-9v20-zq-uPl-38auaE1HnGEQKohUMlja4XXgaQgrlgeFVpGTgyHoSuqkrK4L2SigEXTaNRK86khvqMXE5eH2Fth9RtIO1thM7-3YhpaSGVV_ZokXuDtTHeNSCahTZeG8M4b2pVCaN8cZ1PrmG32KB3uM0J-nvS-yfbbmWX8YcVZa6a8SJ4PQlc-dwxYTje5cz-Cc8ewyvsy7vNjuS_tArwagK-Q1piOgLtzfWksIMPhXrxX-rQ5TcH-Kq_</recordid><startdate>20150805</startdate><enddate>20150805</enddate><creator>Fujiwara, Ryo</creator><creator>Kageyama, Susumu</creator><creator>Tomita, Keiji</creator><creator>Hanada, Eiki</creator><creator>Tsuru, Teruhiko</creator><creator>Yoshida, Tetsuya</creator><creator>Narita, Mitsuhiro</creator><creator>Isono, Takahiro</creator><creator>Kawauchi, Akihiro</creator><general>S. Karger AG</general><general>Karger Publishers</general><scope>M--</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20150805</creationdate><title>Metastatic Prostatic Ductal Adenocarcinoma Successfully Treated with Docetaxel Chemotherapy: A Case Report</title><author>Fujiwara, Ryo ; Kageyama, Susumu ; Tomita, Keiji ; Hanada, Eiki ; Tsuru, Teruhiko ; Yoshida, Tetsuya ; Narita, Mitsuhiro ; Isono, Takahiro ; Kawauchi, Akihiro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c457t-1eafa6bce65973bd5fa540cf912275f1e01f4722255fdd6560a14887e761057a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Chemotherapy</topic><topic>Docetaxel</topic><topic>Prostatic ductal adenocarcinoma</topic><topic>Published: August 2015</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fujiwara, Ryo</creatorcontrib><creatorcontrib>Kageyama, Susumu</creatorcontrib><creatorcontrib>Tomita, Keiji</creatorcontrib><creatorcontrib>Hanada, Eiki</creatorcontrib><creatorcontrib>Tsuru, Teruhiko</creatorcontrib><creatorcontrib>Yoshida, Tetsuya</creatorcontrib><creatorcontrib>Narita, Mitsuhiro</creatorcontrib><creatorcontrib>Isono, Takahiro</creatorcontrib><creatorcontrib>Kawauchi, Akihiro</creatorcontrib><collection>Karger Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Case reports in oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fujiwara, Ryo</au><au>Kageyama, Susumu</au><au>Tomita, Keiji</au><au>Hanada, Eiki</au><au>Tsuru, Teruhiko</au><au>Yoshida, Tetsuya</au><au>Narita, Mitsuhiro</au><au>Isono, Takahiro</au><au>Kawauchi, Akihiro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Metastatic Prostatic Ductal Adenocarcinoma Successfully Treated with Docetaxel Chemotherapy: A Case Report</atitle><jtitle>Case reports in oncology</jtitle><addtitle>Case Rep Oncol</addtitle><date>2015-08-05</date><risdate>2015</risdate><volume>8</volume><issue>2</issue><spage>339</spage><epage>344</epage><pages>339-344</pages><issn>1662-6575</issn><eissn>1662-6575</eissn><abstract>A 68-year-old man presented with gross hematuria. A papillary urethral tumor adjacent to the verumontanum was found by cystourethroscopy. Serum prostate-specific antigen (PSA) was 3.246 ng/ml. A transurethral biopsy specimen was most suggestive of a primary urothelial carcinoma of the prostate, for which a radical cystoprostatectomy was performed. The final pathology was prostatic ductal adenocarcinoma with very focal acinar features (Gleason score 5 + 4 = 9, pT3bN0M0). Local recurrence and pelvic bone metastases developed 17 months later, and his PSA rose to 10.806 ng/ml. He was treated with combined androgen blockade and radiation. Two years later, the lesion showed progressive growth. Treatment followed with docetaxel (70 mg/m 2 every 3 weeks) and prednisolone 5 mg twice daily. After 10 cycles of chemotherapy, all lesions disappeared and PSA decreased to <0.005 ng/ml. Three years after chemotherapy, he maintains a complete response without any additional treatments. Docetaxel chemotherapy can be an effective treatment for patients with recurrent prostatic ductal adenocarcinoma.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>26351443</pmid><doi>10.1159/000438785</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1662-6575 |
| ispartof | Case reports in oncology, 2015-08, Vol.8 (2), p.339-344 |
| issn | 1662-6575 1662-6575 |
| language | eng |
| recordid | cdi_crossref_primary_10_1159_000438785 |
| source | DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Karger Open Access; PubMed Central |
| subjects | Chemotherapy Docetaxel Prostatic ductal adenocarcinoma Published: August 2015 |
| title | Metastatic Prostatic Ductal Adenocarcinoma Successfully Treated with Docetaxel Chemotherapy: A Case Report |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T06%3A50%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Metastatic%20Prostatic%20Ductal%20Adenocarcinoma%20Successfully%20Treated%20with%20Docetaxel%20Chemotherapy:%20A%20Case%20Report&rft.jtitle=Case%20reports%20in%20oncology&rft.au=Fujiwara,%20Ryo&rft.date=2015-08-05&rft.volume=8&rft.issue=2&rft.spage=339&rft.epage=344&rft.pages=339-344&rft.issn=1662-6575&rft.eissn=1662-6575&rft_id=info:doi/10.1159/000438785&rft_dat=%3Cpubmed_cross%3E26351443%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/26351443&rft_doaj_id=oai_doaj_org_article_e1d9e399dc8a48b79d7990118362496d&rfr_iscdi=true |